Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
18h
GlobalData on MSNSuper Bowl ad for copycat weight loss drugs stokes pharma power debateControversy surrounded Him & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
4h
Hosted on MSNHims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugsThe telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...
12h
Stockhead on MSNOzempic’s PBS push could shake up ASX food stocks, and here’s howBig pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...
Hims and Hers has been slammed for its Super Bowl commercial that admonished Americans for being obese and shamed the healthcare industry - then promoted its own weight loss drugs. The 60-second ...
Prescriptions of obesity management drugs have increased, and these increasing trends are associated with online search trends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results